Refine
Has Fulltext
- yes (203)
Is part of the Bibliography
- yes (203)
Year of publication
Document Type
- Journal article (180)
- Doctoral Thesis (22)
- Review (1)
Language
- English (203) (remove)
Keywords
- NFATc1 (13)
- CXCR4 (7)
- apoptosis (7)
- T cells (6)
- glioblastoma (6)
- immunohistochemistry (6)
- lymphoma (6)
- multiple myeloma (6)
- B cells (5)
- Transkriptionsfaktor (5)
- astrocytoma (5)
- cancer (5)
- gene expression (5)
- glioblastoma multiforme (5)
- recurrence (5)
- NFAT (4)
- brain (4)
- breast cancer (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- gene regulation (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- prognosis (4)
- relapse (4)
- therapy (4)
- Apoptosis (3)
- EGFR (3)
- Hodgkin lymphoma (3)
- MYC (3)
- Medizin (3)
- PET/CT (3)
- Proliferation (3)
- biomarker (3)
- cerebrospinal fluid (3)
- forensic neurotraumatology (3)
- germinal center (3)
- glioma (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- thymus (3)
- B-Lymphozyten (2)
- BCL6 (2)
- CD30 (2)
- CRISPR/Cas9 (2)
- Cushing’s syndrome (2)
- DLBCL (2)
- EMT (2)
- Expression (2)
- FGFR (2)
- Glioblastoma (2)
- Graft-versus-leukemia (2)
- HNSCC (2)
- KEAP1 (2)
- Lymphom (2)
- Lymphoma (2)
- Lymphozyten (2)
- MPS1 (2)
- Maus (2)
- Microarray (2)
- Multiple Myeloma (2)
- NAFLD (2)
- NASH (2)
- NSCLC (2)
- Nfatc1 (2)
- PET (2)
- PTCL (2)
- Rhabdomyosarcoma (2)
- T-Lymphozyt (2)
- USP28 (2)
- adrenocortical carcinoma (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- antigen (2)
- brain tumor (2)
- cancer stem cells (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- cytotoxic T cells (2)
- development (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- flow cytometry (2)
- gene (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- in vivo imaging (2)
- inflammation (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- malignant tumors (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- molecular imaging (2)
- mouse models (2)
- mutations (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- proteomics (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- survival (2)
- temozolomide (2)
- transcription (2)
- tumor microenvironment (2)
- vestibular schwannoma (2)
- vitamin D (2)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- ATG7 (1)
- ATM (1)
- Activation (1)
- Activation induced cell death/AICD (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Allogenic hematopoietic stem cell transplantation (1)
- Alpha therapy (1)
- Amplicon Sequencing (1)
- Anergy (1)
- Antibodies (1)
- Antigen (1)
- Antigen CD8 (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Autoantikörper (1)
- Autoimmune diseases (1)
- Autoregulation (1)
- B Lymphocytes (1)
- B cell malignancies (1)
- B-Lymphozyt (1)
- B-MYB (1)
- B-Zell-Leukämie (1)
- B-cell lymphoma (1)
- B-cells (1)
- B-lymphocytes (1)
- BCL2 (1)
- BIRC7 (1)
- Barrett-Ösophagus (1)
- Bauchfellentzündung (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Blimp-1 (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- Burkitt (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C3 (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CD56 (1)
- CD8 (1)
- CD9 (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas-Methode (1)
- CS1 (1)
- CSF (1)
- CTL function (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- CXCR4/SDF-1 (1)
- CXCR5 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Calcineurin (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Cartilage Oligomeric Matrix Protein (1)
- Caspase 12 (1)
- Ccl2 (1)
- Chains (1)
- Chemotherapy (1)
- Childhood (1)
- Cisplatin (1)
- Clonality (1)
- Clonality analysis (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- Cytotoxizität (1)
- DEL(5Q) (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- Diabetes mellitus (1)
- EAHP/SH bone marrow workshop (1)
- EBER in situ hybridization (1)
- EBV (1)
- EGF (1)
- ERM proteins (1)
- EZH1 (1)
- EZH2 (1)
- Epidemiological study (1)
- Epigenese (1)
- Epigenetics (1)
- Epigenetik (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FGF-pathway (1)
- FINCA (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fibrin glue (1)
- Forskolin (1)
- Frequency (1)
- GABP (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- Gallium (1)
- Gen-Anordnung (1)
- Gene (1)
- Gene-expression (1)
- Genexpression (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Genregulation (1)
- Glioma stem cells (1)
- Graft-versus-host-disease (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- Head (1)
- Head and neck cancers (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- Hsp90 (1)
- Hypercortisolism (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IGF1R (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IL-5 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- Images (1)
- Immunisierung (1)
- Immunoreceptors (1)
- Immunosuppression (1)
- Immunotherapy (1)
- Immunrezeptoren (1)
- Immunsystem (1)
- In-vivo (1)
- Inflammation (1)
- Intestinal Intraepithelial Lymphocy (1)
- Iron-oxide (1)
- Irradiation (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Keimzentrum (1)
- Keimzentrumsreaktion (1)
- Kidney cancer (1)
- Killerzelle (1)
- Klonalitaetsanalysen (1)
- Krebs (1)
- Krebs <Medizin> (1)
- LESA (1)
- LITAF (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphocytes (1)
- Lymphomas (1)
- Lymphome (1)
- Lymphozyt (1)
- MDS (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MITF-low (1)
- MIZ1 (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Maschinelles Lernen (1)
- Medical research (1)
- Mensch (1)
- Merlin (1)
- Metastases (1)
- Methylation (1)
- Methylierung (1)
- Molecular pathogenesis (1)
- Molekularbiologie (1)
- Molekulargenetik (1)
- Muskelzelle (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- Mykose (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NF-κB (1)
- NFATc (1)
- NFATc1 sumoylation (1)
- NFATc1/αA (1)
- NFATs (1)
- NFE2L2 (1)
- NHLRC2 (1)
- NIH-3T3 (1)
- NLPHL (1)
- NR3C1 (1)
- NRF2 (1)
- Nestin (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Nodo-parandopathy (1)
- Non Hodgkin Lymphoma (1)
- Non Hodgkin Lymphome (1)
- Nrf2 (1)
- Nuclear expression (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- OncotypeDX\(^{®}\) (1)
- Organoids (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-L1 (1)
- PI3K (1)
- PKA (1)
- PLAG1 rearrangement (1)
- PRRT (1)
- PTEN (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathway (1)
- Pentixafor (1)
- Plasmozytom (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Posttranskriptionelle Regulation (1)
- Pou2af1 (1)
- Profiling (1)
- Prognose (1)
- Prognosis (1)
- Promoter (1)
- Promotor <Genetik> (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNA-Sequenzierung (1)
- RNAPOL1 (1)
- RNAScope (1)
- RYGB (1)
- Random Forest (1)
- Rats (1)
- Receptor-Tyrosine Kinases (1)
- Regulatorgen (1)
- Regulatory-cells (1)
- Renal cell carcinoma (1)
- Rezeptor-Tyrosinkinasen (1)
- Rheumatoid arthritis (1)
- Rheumatoide Arthritis (1)
- Rho-GTPases (1)
- Richter's syndrome (1)
- Richter-Syndrom (1)
- Rituximab plus (1)
- Riutximab (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SOAT1 (1)
- SSTR (1)
- Sequenzdaten (1)
- Signaltransduktion (1)
- Soft-tissue infection (1)
- Sox9 (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sprue (1)
- Starry Sky (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- Synovialmembran (1)
- T cell differentiation (1)
- T cell receptors (1)
- T lymphocyte (1)
- T(H)17 cells (1)
- T-Zellen (1)
- T-cell lymphoma (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-cells (1)
- T-follicular regulatory cell (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- TTK (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Temozolomide (1)
- Th (1)
- Th17 (1)
- Thymocytes (1)
- Tlymphozyten (1)
- Tracking (1)
- Transcription factors (1)
- Transcription-factor (1)
- Transkriptionfaktoren (1)
- Translational research (1)
- Tregs (1)
- Tumor (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumour markers (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- Vorhersage (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- Zellmigration (1)
- Zellzyklus (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activation (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- affinity (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- allografts (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- antibodies (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- apoptosis, Myc (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantibody (1)
- autoantigen (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biosynthesis (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastasis (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- buparlisib (1)
- c-MYC (1)
- c-myc (1)
- cAMP (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- cartilage oligomeric matrix protein (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemokine receptor-4 (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosomal aberration (1)
- chromosomes (1)
- chronic lymphocytic leukemia (1)
- chronische B-Zell Leukaemie (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- cleavage (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- combined immunodeficiency (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- complex (1)
- consensus DNA (1)
- cross-priming (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporine A (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deformation (1)
- deletions (1)
- diffuse large B-cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- discriminant analysis (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- early breast cancer (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis lethargica (1)
- enhancer (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorescence in situ hybridisation (1)
- follicular T helper cells (1)
- follicular lymphoma (1)
- follicular regulatory T cell (1)
- follikuläre regulatorische T-Zelle (1)
- forecasting (1)
- formalin (1)
- functional characterization (1)
- fungal infection (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- grade 3B (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- gut–liver axis (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- humoral immunity (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunology and microbiology section (1)
- immunotherapeutics (1)
- immunotherapy (1)
- in silico analysis (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- inflammation-induced tissue demage (1)
- integrin (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- kinetic mechanism (1)
- knock down (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- mRNA expression (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- medical research (1)
- medicine (1)
- melanoma (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microvessel permeability (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular diagnostics (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse model (1)
- mtDNA (1)
- multifocal growth (1)
- multigene-array (1)
- multiple sclerosis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutational targeting (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neuromelanin (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nicotinic acetylcholine receptor (1)
- nodular lymphcyte (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- obinutuzumab (1)
- olfactory bulb (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- p53 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panniculitis (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathogenesis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- postencephalitic parkinsonism (1)
- precision oncology (1)
- prediction (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- principal component analysis (1)
- prognostic factor (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- prostate cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- radiotherapy (1)
- rag (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T cells (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- rheumatoid arthritis (1)
- rheumatoiden Arthritis (1)
- ribosome (1)
- ribosyltransferase (1)
- roquin (1)
- salivary gland neoplasia (1)
- salivary gland tumors (1)
- salivary glands (1)
- scoring system (1)
- seminoma (1)
- senescence (1)
- serum (1)
- signal transduction (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- spinal-cord-injury (1)
- splice variant (1)
- squamous tumors (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t cells (1)
- t-SNE (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- targeted therapy (1)
- tauopathy (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymoma (1)
- tissue preparation (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcription factors (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translocation (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treg cells (1)
- triple-negative breast cancer (1)
- tumor heterogeneity (1)
- tumor immunology (1)
- tumor slice cultures (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumour heterogeneity (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unsupervised clustering (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (203) (remove)
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier.
Purpose
While [\(^{18}\)F]-fluorodeoxyglucose ([\(^{18}\)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT.
Methods
Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [\(^{18}\)F]FDG and [\(^{68}\)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV\(_{max}\)) and peak (SUV\(_{peak}\) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference.
Results
[\(^{18}\)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUVmax of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUVpeak of 16.1 ± 10.3 ([\(^{18}\)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [\(^{18}\)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples.
Conclusion
FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted.
The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.
Background
Panniculitis-like T-cell lymphoma is an uncommon type of non-Hodgkin lymphoma, occurring usually in the form of nodules within the subcutaneous fat tissue of the extremities or trunk. In the literature, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is described as a distinct type of T-cell lymphoma with a variable clinical behavior, depending on molecular phenotype of T-cell receptor (TCR) and on the presence or absence of hemophagocytic syndrome.
Case presentation
We present a bioptic and autoptic case of a 65-years old Caucasian man with panniculitic T-cell lymphoma with morphological and immunohistochemical features of SPTCL, limited to the retroperitoneal and mesenteric mass, i.e. without any cutaneous involvement, and associated with severe hemophagocytic lymphohistiocytosis.
Conclusion
A panniculitic T-cell lymphoma with morphological and molecular features of SPTCL, which is limited to mesentery, i.e. does not involve subcutaneous fat, seems to be exceedingly rare.
Routine coronal paraffin-sections through the dorsal frontal and parieto-occipital cortex of a total of sixty cases with divergent causes of death were immunohistochemically (IHC) stained with an antibody against TMEM119. Samples of cerebrospinal fluid (CSF) of the same cases were collected by suboccipital needle-puncture, subjected to centrifugation and processed as cytospin preparations stained with TMEM119. Both, cytospin preparations and sections were subjected to computer-assisted density measurements. The density of microglial TMEM119-positive cortical profiles correlated with that of cytospin results and with the density of TMEM119-positive microglial profiles in the medullary layer. There was no statistically significant correlation between the density of medullary TMEM119-positive profiles and the cytospin data. Cortical microglial cells were primarily encountered in supragranular layers I, II, and IIIa and in infragranular layers V and VI, the region of U-fibers and in circumscribed foci or spread in a diffuse manner and high density over the white matter. We have evidence that cortical microglia directly migrate into CSF without using the glympathic pathway. Microglia in the medullary layer shows a strong affinity to the adventitia of deep vessels in the myelin layer. Selected rapidly fatal cases including myocardial infarcts and drowning let us conclude that microglia in cortex and myelin layer can react rapidly and its reaction and migration is subject to pre-existing external and internal factors. Cytospin preparations proved to be a simple tool to analyze and assess complex changes in the CNS after rapid fatal damage. There is no statistically significant correlation between cytospin and postmortem interval. Therefore, the quantitative analyses of postmortem cytospins obviously reflect the neuropathology of the complete central nervous system. Cytospins provide forensic pathologists a rather simple and easy to perform method for the global assessment of CNS affliction.
Hyper-IgM syndrome type 2 (HIGM2) is a B cell intrinsic primary immunodeficiency caused by mutations in AICDA encoding activation-induced cytidine deaminase (AID) which impair immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM). Whereas autosomal-recessive AID-deficiency (AR-AID) affects both CSR and SHM, the autosomal-dominant form (AD-AID) due to C-terminal heterozygous variants completely abolishes CSR but only partially affects SHM. AR-AID patients display enhanced germinal center (GC) reactions and autoimmune manifestations, which are not present in AD-AID, suggesting that SHM but not CSR regulates GC reactions and peripheral B cell tolerance. Herein, we describe two siblings with HIGM2 due to a novel homozygous AICDA mutation (c.428-1G > T) which disrupts the splice acceptor site of exon 4 and results in the sole expression of a truncated AID variant that lacks 10 highly conserved amino acids encoded by exon 4 (AID-ΔE4a). AID-ΔE4a patients suffered from defective CSR and enhanced GC reactions and were therefore indistinguishable from other AR-AID patients. However, the AID-ΔE4a variant only partially affected SHM as observed in AD-AID patients. In addition, AID-ΔE4a but not AD-AID patients revealed impaired targeting of mutational hotspot motives and distorted mutational patterns. Hence, qualitative defects in AID function and altered SHM rather than global decreased SHM activity may account for the disease phenotype in these patients.
Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
Due to the wide variety of benign and malignant salivary gland tumors, classification and malignant behavior determination based on histomorphological criteria can be difficult and sometimes impossible. Spectroscopical procedures can acquire molecular biological information without destroying the tissue within the measurement processes. Since several tissue preparation procedures exist, our study investigated the impact of these preparations on the chemical composition of healthy and tumorous salivary gland tissue by Fourier-transform infrared (FTIR) microspectroscopy. Sequential tissue cross-sections were prepared from native, formalin-fixed and formalin-fixed paraffin-embedded (FFPE) tissue and analyzed. The FFPE cross-sections were dewaxed and remeasured. By using principal component analysis (PCA) combined with a discriminant analysis (DA), robust models for the distinction of sample preparations were built individually for each parotid tissue type. As a result, the PCA-DA model evaluation showed a high similarity between native and formalin-fixed tissues based on their chemical composition. Thus, formalin-fixed tissues are highly representative of the native samples and facilitate a transfer from scientific laboratory analysis into the clinical routine due to their robust nature. Furthermore, the dewaxing of the cross-sections entails the loss of molecular information. Our study successfully demonstrated how FTIR microspectroscopy can be used as a powerful tool within existing clinical workflows.
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.
While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.